Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children

Ilske Oschlies,[1] Birgit Burkhardt,[2] Itziar Salaverria,[3] Andreas Rosenwald,[4] Emanuele S.G. d'Amore,[5] Monika Szczepanowski,[1] Karoline Koch,[1] Martin L. Hansmann,[6] Harald Stein,[7] Peter Möller,[8] Alfred Reiter,[2] Martin Zimmermann,[9] Angelo Rosolen,[10] Reiner Siebert,[3] Elaine S. Jaffe,[10] and Wolfram Klapper[1]

[1]Department of Pathology, Hematopathology Section and Lymph Node Registry, Christian-Albrechts-University, Kiel, & University Hospital Schleswig-Holstein, Campus Kiel, Germany; [2]NHL-BFM Study Center, Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany; [3]Institute of Human Genetics, Christian-Albrechts-University, Kiel, & University Hospital Schleswig-Holstein, Campus Kiel, Germany; [4]Department of Pathology, University of Würzburg, Würzburg, Germany; [5]Department of Pathology, Ospedale San Bortolo, Vicenza, Italy [6]Department of Pathology, University of Frankfurt, Frankfurt, Germany; [7]Department of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany; [8]Department of Pathology, University of Ulm, Ulm, Germany; [9]Departments of Pediatric Hematology and Oncology, University of Hannover, Germany; [10]Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera, Dipartimento di Pediatria, Università di Padova, Padua, Italy, and [11]Hematopathology Section, Laboratory of Pathology, Institutes of Health, Bethesda, MD, USA

Citation: Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, G. d'Amore ES, Szczepanowski M, Koch K, Hansmann ML, Stein H, Möller P, Reiter A, Zimmermann M, Rosolen A, Siebert R, Jaffe ES, and Klapper W. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011;96(2):262-268. doi:10.3324/haematol.2010.030809

Online Supplementary Table S1. Probes used for fluorescence *in situ* hybridization (FISH).

FISH assay Probe name	Company	Chromosomal location Chromosomal band	Fluorescent dye
LSI *MYC* BAP	Abbot, IL, USA	8q24	Spectrum green/Spectrum orange
Clone name	**Vector type**	**Genomic localization of insert (bp)***	**Fluorescent dye**
REL_BCL11A BAP		**2p16.1**	
RP11-158i21	BAC	chr2:60,384,383-60,555,229	Spectrum orange
RP11-440P5(AC009970)	BAC	chr2:60,553,094-60,690,102	Spectrum orange
RP11-498O5 (AC011245)	BAC	chr2:60,870,204-60,927,384	Spectrum green
RP11-373L24	BAC	chr2:60,927,185-61,136,244	Spectrum green
JAK2_PDL2 **BAP**		**9p24.1**	
RP11-125K10	BAC	chr9:4,819,656-4,991,841	Spectrum orange
RP11-39K24	BAC	chr9:5,008,714-5,181,904	Spectrum orange
RP11-635N21	BAC	chr9:5,507,366-5,639,598	Spectrum green
RP11-574F11	BAC	chr9:5,574,490-5,578,994	Spectrum green

*BAC- clones were obtained from the RZPD Deutsches Ressourcenzentrum für Genomforschung GmbH (Berlin, Germany) and from Invitrogen (Karlsruhe, Germany); *NCBI Build 36.1*

Online Supplementary Table S2. Summary of histopathological, immunohistochemical and FISH analyses.

		Immunohistochemistry													FISH		
N.	Consensus diagnosis	CD20	CD79a	CD30	CD15	CD23	CD5	CD10	Pax5	Oct2	BOB1	BCL6	MUM1	EBER	8q (MYC)	6p (REL/BCL11A)	9p (JAK2/PDL2)
1	B-NHL, NOS	4	4	3	0	1	0	4	4	4	3	4	3	na	na	wt	gain
2	PMBCL	4	4	4	0	2	0	0	4	4	na	3	3	0	wt	gain	gain
3	PMBCL	4	4	4	0	1	0	0	4	4	3	2	2	0	wt	nd	nd
4	B-NHL, NOS	4	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd
5	PMBCL	4	3	1	0	0	0	3	4	4	0	1	3	0	wt	wt	wt
6	PMBCL	4	nd	0	nd	2	nd	0	nd	nd	nd	na	nd	nd	nd	nd	nd
7	PMBCL	4	3	3	0	2	nd	0	nd	nd	nd	4	nd	0	wt	wt	wt
8	PMBCL	4	4	0	0	0	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd
9	PMBCL	4	4	4	0	0	0	3	4	4	1	3	1	0	wt	wt	wt
10	PMBCL	4	4	3	0	1	0	0	4	4	1	3	na	0	gain	gain	amplification
11	PMBCL	4	4	2	0	0	0	3	4	4	1	na	2	0	wt	wt	wt
12	PMBCL	4	3	3	0	0	0	4	4	4	2	na	3	0	na	wt	gain+break
13	PMBCL	4	nd	1	0	1	nd	0	nd	nd	nd	2	2	0	nd	nd	nd
14	PMBCL	4	nd	na	0	0	nd	na	nd	nd	nd	na	nd	nd	nd	nd	nd
15	PMBCL	4	4	0	0	2	0	0	4	4	0	3	2	0	wt	gain	gain
16	PMBCL	4	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd
17	PMBCL	4	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd
18	PMBCL	4	4	4	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd
19	PMBCL	4	4	nd	0	0	0	nd	4	4	1	3	nd	0	gain	wt	gain
20	PMBCL	4	nd	nd	nd	4	0	0	nd	nd	nd	4	4	nd	nd	nd	nd
21	DLBCL	4	nd	0	0	0	nd	0	nd	nd	nd	4	nd	nd	Break t(2;8)	gain	amlification
22	PMBCL	4	4	3	0	2	nd	0	4	nd	nd	nd	nd	nd	nd	nd	nd
23	PMBCL	4	4	4	0	1	0	0	4	4	na	4	na	0	wt	wt	gain
24	PMBCL	4	4	4	0	4	na	3	4	4	1	4	4	0	wt	gain	gain
25	PMBCL	4	4	1	0	3	0	4	4	4	2	2	3	0	na	gain	amplification
26	PMBCL	4	4	4	0	3	nd	na	nd	nd	nd	nd	nd	nd	break + amplification	amplification	amplification
27	PMBCL	4	4	0	0	3	0	0	4	na	na	2	3	0	wt	wt	wt
28	DLBCL	4	nd	0	nd	nd	nd	4	nd	nd	nd	4	3	nd	nd	nd	nd
29	PMBCL	4	4	3	0	4	0	0	4	3	na	1	na	0	wt	amplification	wt
30	MGZL	4	4	4	1	nd	nd	1	4	nd	nd	nd	nd	nd	nd	nd	nd
31	PMBCL	4	4	4	0	0	nd	4	nd	nd	nd	nd	nd	nd	gain	wt	amplification
32	PMBCL	4	4	4	0	2	0	0	4	4	na	3	2	0	na	nd	nd
33	PMBCL	4	nd	0	nd	0	nd	0	nd	nd	nd	nd	nd	nd	nd	wt	wt
34	MGZL	4	4	4	0	3	0	0	4	3	0	0	4	0	wt	wt	wt
35	PMBCL	4	4	3	0	0	0	0	4	4	na	1	0	0	nd	nd	nd
36	PMBCL	0	4	4	0	0	0	0	4	4	4	3	0	0	nd	nd	nd
37	PMBCL	4	nd	0	0	2	0	0	nd	nd	nd	nd	nd	nd	nd	nd	nd
38	PMBCL	4	4	3	0	0	0	0	4	4	na	1	0	0	nd	nd	nd
39	PMBCL	4	4	3	nd	0	0	0	4	4	3	nd	0	0	nd	nd	nd
40	PMBCL	4	3	2	0	0	0	0	2	3	na	0	0	0	nd	nd	nd
41	PMBCL	4	4	1	0	2	0	0	4	4	3	3	0	0	nd	nd	nd
42	PMBCL	4	2	2	0	3	0	0	3	3	2	2	1	0	nd	nd	nd
43	PMBCL	4	2	0	0	4	0	0	4	3	na	3	0	0	nd	nd	nd
44	PMBCL	4	4	0	0	4	0	0	3	3	3	2	0	0	nd	nd	nd
45	PMBCL	4	4	0	0	3	0	0	4	4	4	1	3	0	nd	nd	nd
46	PMBCL	4	4	3	0	4	0	0	4	4	4	2	2	0	nd	nd	nd
47	MGZL	4	4	2	0	4	0	0	3	4	4	1	2	3	nd	nd	nd
48	PMBCL	4	4	1	0	3	0	0	4	4	4	3	2	0	nd	nd	nd
49	MGZL	4	3	3	0	2	0	0	3	3	2	0	3	2	nd	nd	nd
50	PMBCL	4	nd	nd	nd	4	nd	4	nd	nd	nd	nd	nd	nd	nd	nd	nd
51	PMBCL	4	4	2	0	4	0	nd	2	2	3	1	4	0	nd	nd	nd
52	PMBCL	4	4	4	0	4	0	nd	3	3	4	2	2	0	nd	nd	nd

B-NHL. NOS: B-cell non-Hodgkin's lymphoma, not otherwise specified, PMBCL: primary mediastinal large B-cell lymphoma, MGZL: mediastinal gray zone lymphoma, na: not analyzable, nd: not determined; immunohistochemistry: 0: negative, 1 = 1-25% positive tumor cells, 2 = 26-50% positive tumor cells, 3 = 51-75% positive tumor cells, 4 = >75% tumor cells; FISH: wt = wild type.